Alpha Tau Medical Ltd. (DRTS) Form 6-K — Oct 22, 2026
Alpha Tau Medical signed an MOU with Samsung Medical Center in Seoul to explore a potential clinical trial of Alpha DaRT in pancreatic cancer patients, which would be the therapy's first trial in South Korea. Samsung Medical Center is ranked fifth in the world and number one in Korea in oncology, and its Pancreatobiliary Cancer Center has performed more than 4,000 pancreatectomies between 2008 and 2025.
Key figures
- Smc oncology rank
- fifth in world, first in Korea (Newsweek 2027)
- Korea five year survival rate
- 17.0%
- Smc pancreatectomies 2008 2025
- more than 4,000
- Korea pancreatic diagnoses 2023
- 9748
- Korea pancreatic death rate increase 2025
- over 6%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.